219
Participants
Start Date
March 9, 2023
Primary Completion Date
July 21, 2025
Study Completion Date
July 31, 2027
TQB2102 injection
TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against HER2, a enzyme-cleavable linker, and a topoisomerase I inhibitor payload.
The First Hospital of China Medical University, Shenyang
Harbin Medical University Cancer Hospital, Harbin, China, Harbin
Fudan University shanghai Cancer Center, Shanghai
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Shanghai
The First Affiliated Hospital of Nanjing Medical University, Nanjing
Fujian Cancer Hospital., Fuzhou
Hunan Cancer Hospital, Changsha
The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou
Sun Yat-sen University Cancer Center, Guangzhou
West China Hospital, Sichuan University, Chengdu
Mianyang Central Hospital, Mianyang
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
INDUSTRY